

1 **RESIST ACINETO test for the rapid detection of NDM and OXA acquired carbapenemases**
2 **directly from blood culture in *Acinetobacter* species**

3
4 Anaïs Potron^{1,2#}, Marion Daniel^{3#}, Mila Bay¹, Pauline Choulet¹, Thomas Garrigos^{3,4}, Loïk
5 Sababadichetty³, Olivier Belmonte⁴, Damien Fournier¹, Katy Jeannot^{1,2#} and Guillaume Miltgen^{3,4,5#}.

6
7 1 Laboratoire Associé au Centre National de Référence de la Résistance aux Antibiotiques, Centre
8 Hospitalier Universitaire de Besançon, F-25000 Besançon, France.

9 2 Université de Franche-Comté, CNRS, UMR 6249 Chrono-environnement, F-25000 Besançon, France.

10 3 UMR Processus Infectieux en Milieu Insulaire Tropical, CNRS 9192, INSERM U1187, IRD 249,
11 Université de La Réunion, 97490, Saint-Clotilde, La Réunion, France.

12 4 Laboratoire de Bactériologie, Centre Hospitalier Universitaire de La Réunion, site Félix Guyon,
13 97400, Saint-Denis, La Réunion, France.

14 5 Centre Régional en Antibiothérapie de La Réunion (CRAtb Réunion), Saint-Pierre, La Réunion,
15 France.

16 # These authors contributed equally to the study.

17

18

19 *** Corresponding author:**

20 Guillaume Miltgen:

21 e-mail address: guillaume.miltgen@chu-reunion.fr ; phone number: +262 6 92 36 96 57

22 postal address: Laboratoire de Bactériologie, CHU Félix Guyon, Allée des Topazes, 97400 Saint-Denis,

23 La Réunion, France

24

25 **Running title:** Rapid detection of carbapenemases in *Acinetobacter* sp

26

27

28 **Keywords**

29 *Acinetobacter*, carbapenemases, OXA-23, OXA-24/40, OXA-58, NDM, rapid detection, blood culture.

30 **Abstract**

31

32 The immunochromatographic assay RESIST ACINETO (Coris BioConcept) was evaluated on a
33 collection of 121 *Acinetobacter* spp. clinical isolates, including 104 carbapenemase producers. The
34 strains producing carbapenemases OXA-23, -40, -58, or/and NDM were accurately detected from
35 bacterial cultures and directly from blood cultures, with the exception of an OXA-23/NDM-1-positive
36 *A. radioresistens* isolate (only detected through standard culture). The performance of the RESIST
37 ACINETO test was excellent (sensitivity 99%, specificity 100%) on this collection of isolates.

38 Carbapenem-resistant *Acinetobacter baumannii* (CRAB) poses a significant global threat,
39 leading to a high mortality rate associated with antimicrobial resistance (1). This multidrug- or
40 extensively drug-resistant pathogen is identified by the WHO as one of the three critical priority
41 bacteria requiring urgent development of new antibiotics (2). In *Acinetobacter* species, the major
42 mechanism for carbapenem resistance is attributed to the production of carbapenem-hydrolysing
43 class D beta-lactamases, including OXA-23, OXA-24/40, and OXA-58 groups (3). Additionally,
44 emerging NDM class B metallo-beta-lactamases play a significant role in conferring resistance (4,5).
45 Since the activity of the last-line antibiotics, such as the newly developed cefiderocol, depend on the
46 type of carbapenemase, rapid detection of these carbapenemase-producing bacteria has become
47 crucial for optimizing antibiotherapy in case of infection and implementing appropriate hygiene
48 measures (6). In recent years, several rapid immunochromatographic tests (Coris BioConcept, NG
49 Biotech) have been developed for the detection of carbapenemase-producing Enterobacterales ; but
50 none has been specifically designed for non-fermenting Gram-negative bacilli, with the exception of
51 the Coris OXA-23 K-SET test (accurate detection of OXA-23 group carbapenemases) (7–9). The novel
52 RESIST ACINETO test (Coris BioConcept) has recently been developed to detect the main
53 carbapenemases identified in the *Acinetobacter* species, namely the OXA-23-, OXA-24/40-, OXA-58-
54 and NDM-groups (10). Here, we evaluated the performance of this novel immunochromatographic
55 assay for the detection of carbapenemase-producing *Acinetobacter* spp. encountered in mainland
56 and overseas France, from standard and blood cultures.

57 A large collection of 121 well-characterised *Acinetobacter* spp. clinical strains were selected
58 from the French National Reference Center for Antibiotic Resistance (FNRC-AR) ($n=61$) and the
59 University hospital of Reunion Island ($n=60$). The isolates were identified to the species level using
60 matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MALDI
61 Biotyper; Bruker Daltonics) or by sequencing. The collection included 107 isolates of *A. baumannii*
62 *calcoaceticus* complex (*A. baumannii* $n=95$, *A. pittii* $n=10$, *A. nosocomialis* $n=2$), 7 *A. ursingii*, 1
63 *A. haemolyticus*, 1 *A. johnsonii*, 1 *A. junii*, 1 *A. proteolyticus*, 1 *A. radioresistens*, 1 *A. townnerii* and 1

64 *A. variabilis*. One hundred and four strains produced one ($n=75$) or two carbapenemases ($n=29$)
65 including 97 enzymes targeted by the test (27 OXA-23 type, 14 OXA-24/40 type, 6 OXA-58 type, 21
66 NDM type, 16 OXA-23+NDM-1, 3 OXA-58+NDM-1 and 10 others carbapenemase combinations)
67 (Table S1). Three non-targeted carbapenemase, IMP-63 ($n=1$) et VIM-4 ($n=2$), were included, as well
68 as 4 carbapenemase-hydrolyzing class D beta-lactamases (CHDL) rarely identified, OXA-235 ($n=1$),
69 OXA-255 ($n=2$) and OXA-679 ($n=1$) (Table 1).

70 The performance of the RESIST ACINETO test was evaluated according to the manufacturer's
71 recommendations from standard and blood cultures. From bacterial colonies, a 1 μ L full calibrated
72 loop of bacteria grown for 16-24h at 35+/-2°C on Mueller-Hinton agar plate (bioMérieux) was added
73 to 6 drops of lysis buffer. After homogenisation, 100 μ L of the solution was added to the cassette.
74 From blood culture, a blood culture vial (BACTEC Plus Aerobic/F, Becton Dickinson) was inoculated
75 with 1 mL of a bacterial suspension calibrated at 10^2 UFC/mL and incubated. Then, 1mL of the
76 positive blood culture was collected and treated with the RESIST-BC protocol, as recommended by
77 the manufacturer (Figure S1). Finally, 100 μ L of the extraction solution was transferred into the
78 cassette. The reading of cassettes was performed by two operators in a double-blind after 15 min.
79 The sensitivity and specificity of the tests were calculated using the online program of the
80 VassarStats website (<http://vassarstats.net>).

81 For the 97 carbapenemase-producing strains targeted by the test, all enzymes were correctly
82 detected from standard and blood cultures, except for the *A. radioresistens* isolate (OXA-23 + NDM-
83 1), where both enzymes were only detected from the standard culture (Table 1). However,
84 carbapenem resistant *A. radioresistens* isolates are very rare, representing less than 0.1% of
85 *Acinetobacter* species received at the FNRC-AR between 2013 and 2023. Seven NDM-producing
86 strains have a low intensity band particularly from blood culture, with no inter-operator discordance
87 and was considered positive according to the manufacturer's recommendations (Figure 1).
88 Interestingly, the test detected in both growth conditions, the strains producing the OXA-255 ($n=2$)
89 and OXA-679 ($n=1$) enzymes, which share 87% and 73% amino acid identity with OXA-24/40,

90 respectively (these strains were considered true positives for the performance calculation) (15).
91 However, the test failed to detect the OXA-235 enzyme, which shares an amino acid identity lower
92 than 65% with the enzymes OXA-24/40 (59%), OXA-23 (61%), and OXA-58 (64%). No false positives
93 were observed for the strains producing a non-targeted carbapenemase (IMP-63 and VIM-4) or other
94 beta-lactamases (CTX-M-, GES-, PER-, CARB-, RTG-, TEM-types) (Table 1). The test exhibited a
95 sensitivity of 100% in standard cultures and 99% in blood cultures, while demonstrating a specificity
96 of 100% in both conditions. Thus, the RESIST ACINETO test proves to be a reliable method for
97 detecting carbapenemases in *Acinetobacter* species, as demonstrated by two recent studies (10,11)
98 focusing on standard cultures. In our study, we extended the evaluation to blood culture, revealing
99 consistent results with the previous findings.

100 These results opens up new potential applications for the test based on blood cultures (11).
101 The use of the RESIST ACINETO test could prove highly beneficial for countries with a high frequency
102 of carbapenem-resistant *Acinetobacter* species isolates, particularly in cases where the *A. baumannii-*
103 *calcoaceticus complex* is responsible for a significant proportion of healthcare-associated bacteremia
104 (e.g. South East Asia and the Balkans) (12,13). When performed directly after the presumptive
105 identification of Gram-negative (coco-)bacilli in a positive blood culture, this test could facilitate the
106 early detection imipenem-resistant isolates. It may also enable the optimization of treatment based
107 on the type of carbapenemase present. It is well established that the MIC of cefiderocol against
108 NDM-producing *A. baumannii* isolates are typically higher than 2 mg/L (6). This test could further
109 assist in directing treatment towards alternative therapeutic options.

110 In conclusion, the RESIST ACINETO test is a rapid, easy-to-use, and cost-effective test that
111 demonstrates excellent performance in detecting the major acquired carbapenemases present in the
112 *Acinetobacter* species. It has the potential to be considered as an option for routine use in
113 microbiology laboratories.

114 **Acknowledgments**

115

116 This work was partially supported by the French Ministry of Health *via* Santé Publique France, and

117 the ERDF European program (RESISTO-RUN project, 20201126-0022906).

118 We would also like to thank Coris BioConcept for supplying the kits. We precise Coris BioConcept was

119 not involved in the design of the study or analysis of the results.

120

121

122 References

- 123 1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in
124 2019: a systematic analysis. *Lancet*. 2022 Feb 12;399(10325):629–55.
- 125 2. WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. Available
126 from: [https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-](https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)
127 [antibiotics-are-urgently-needed](https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed).
- 128 3. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in *Pseudomonas aeruginosa*
129 and *Acinetobacter baumannii*: Mechanisms and epidemiology. *Int J Antimicrob Agents*. 2015
130 Jun;45(6):568–85.
- 131 4. Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative
132 bacteria. *Clin Infect Dis*. 2019 Nov 13;69(Suppl 7):S521–8.
- 133 5. Hsu LY, Apisarnthanarak A, Khan E, Suwantararat N, Ghafur A, Tambyah PA. Carbapenem-resistant
134 *Acinetobacter baumannii* and *Enterobacteriaceae* in South and Southeast Asia. *Clin Microbiol Rev*.
135 2017 Jan;30(1):1–22.
- 136 6. Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-
137 susceptibility in Enterobacterales, *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and
138 *Stenotrophomonas maltophilia*: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2023
139 Sep 2;S1198-743X(23)00413-5.
- 140 7. Rösner S, Kamalanabhaiah S, Küsters U, Kolbert M, Pfennigwerth N, Mack D. Evaluation of a novel
141 immunochromatographic lateral flow assay for rapid detection of OXA-48, NDM, KPC and VIM
142 carbapenemases in multidrug-resistant *Enterobacteriaceae*. *J Med Microbiol*. 2019
143 Mar;68(3):379–81.
- 144 8. Bernabeu S, Bonnin RA, Dortet L. Comparison of three lateral flow immunochromatographic
145 assays for the rapid detection of KPC, NDM, IMP, VIM and OXA-48 carbapenemases in
146 Enterobacterales. *J Antimicrob Chemother*. 2022 Oct 28;77(11):3198–205.
- 147 9. Fournier D, Triponney P, Gabriel L, Plésiat P, Jeannot K, Potron A. Evaluation of 5 rapid
148 colorimetric and immunochromatographic tests for the detection of carbapenemases in
149 *Pseudomonas aeruginosa* and *Acinetobacter* spp. isolates. *Eur J Clin Microbiol Infect Dis*. 2023
150 Aug;42(8):1043–5.
- 151 10. Mertins S, Higgins PG, Thunissen C, Magein H, Gillemann Q, Mertens P, González Rodríguez M,
152 Maus LM, Seifert H, Krönke M, Klimka A. Development of an immunochromatographic lateral flow
153 assay to rapidly detect OXA-23-, OXA-40-, OXA-58- and NDM-mediated carbapenem resistance
154 determinants in *Acinetobacter baumannii*. *J Med Microbiol*. 2023 Apr;72(4).
- 155 11. Bouvier M, Kerbol A, Findlay J, Freire S, Poirel L, Nordmann P. Resist Acineto rapid immunological
156 test for the detection of acquired carbapenemase producers among *Acinetobacter* spp. *Diagn*
157 *Microbiol Infect Dis*. 2023 Aug 9;107(3):116043.
- 158 12. Healthcare-associated infections acquired in intensive care units. Annual Epidemiological Report
159 for 2019. ECDC, 2023 May. [Internet]. Available from:
160 [https://www.ecdc.europa.eu/sites/default/files/documents/healthcare-associated-infections-](https://www.ecdc.europa.eu/sites/default/files/documents/healthcare-associated-infections-intensive-care-units-annual-epidemiological-report-2019.pdf)
161 [intensive-care-units-annual-epidemiological-report-2019.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/healthcare-associated-infections-intensive-care-units-annual-epidemiological-report-2019.pdf)

162 13. Gajic I, Jovicevic M, Popadic V, Trudic A, Kabic J, Kekic D, Ilic A, Klasnja S, Hadnadjev M, Popadic
163 DJ, Andrijevic A, Prokic A, Tomasevic R, Ranin L, Todorovic Z, Zdravkovic M, Opavski N. The
164 emergence of multi-drug-resistant bacteria causing healthcare-associated infections in COVID-19
165 patients: a retrospective multi-centre study. *J Hosp Infect.* 2023 Jul;137:1–7.

166 14. Miltgen G, Bour M, Allyn J, Allou N, Vedani T, Vuillemenot JB, Triponney P, Martinet O, Lugagne
167 N, Benoit-Cattin T, Dortet L, Birer A, Jaffar-Bandjee M-C, Belmonte O, Plésiat P, Potron A. Molecular
168 and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing *Acinetobacter*
169 *baumannii* outbreak in the Southwest Indian Ocean Area. *Int J Antimicrob Agents.* 2021
170 Oct;58(4):106402.

171 15. Tietgen M, Kramer JS, Brunst S, Djahanschiri B, Wohra S, Higgins PG, Weidensdorfer M, Riedel-
172 Christ S, Pos KM, Gonzaga A, Steglich M, Nübel U, Ebersberger I, Proschak E, Göttig S. Identification of
173 the novel class D β -lactamase OXA-679 involved in carbapenem resistance in *Acinetobacter*
174 *calcoaceticus*. *J Antimicrob Chemother.* 2019 Jun 1;74(6):1494–502.

175

176

177

178 **Appendices**

179 **Figure's legend**

180 Figure 1. Representation of RESIST ACINETO test results for some isolates of interest.

181

182 **Table's legend**

183 Table 1. Coris ACINETO results obtained with bacterial and blood cultures on the 121 isolates tested.

184 P: positive; N: negative.

185

186 **Supplemental material**

187

188 Figure S1: Blood culture sample processing protocol (adapted from RESIST-BC protocol, Coris
189 BioConcept, technical note n°IFU-57S01/FR/V02, <https://www.corisbio.com/products/resist-acineto>).

190

191 Table S1: Molecular characteristics of the 121 *Acinetobacter* spp. isolates included in the study.

192 Strains originating in mainland France are marked as "France", strains originating in overseas
193 territories are marked with a distinctive sign ([‡] Guadeloupe, [♦] Guyane, [#] Mayotte, ^{*} Reunion). The 4
194 light grey lines correspond to the rare oxacillinase variants (OXA-235, OXA-255, OXA-679) tested. The
195 dark grey line corresponds to the *A. radioresistens* OXA-23+NDM-1 strain not detected in blood
196 culture.

197




Figure 1. Representation of RESIST ACINETO test results for some isolates of interest.

Table 1. Coris ACINETO results obtained with bacterial and blood cultures on the 121 isolates tested.

Category	Species	Resistance mechanism	Number of strains	Coris ACINETO results obtained with bacterial culture			% Sensitivity (95% CI)	% Specificity (95% CI)	Coris ACINETO results obtained with blood culture			% Sensitivity (95% CI)	% Specificity (95% CI)
				OXA-40/58	OXA-23	NDM			OXA-40/58	OXA-23	NDM		
OXA-23 type (n=27)	<i>Acinetobacter</i> spp.	OXA-23	25	N	P	N	100 (88-100)	100 (88-100)	N	P	N	100 (88-100)	100 (88-100)
	<i>Acinetobacter</i> spp.	OXA-565	2	N	P	N			N	P	N		
OXA-24/40 type (n=14)	<i>Acinetobacter baumannii</i>	OXA-24	5	P	N	N	100 (78-100)	100 (78-100)	P	N	N	100 (78-100)	100 (78-100)
	<i>Acinetobacter baumannii</i>	OXA-72	9	P	N	N			P	N	N		
OXA-58 type (n=6)	<i>Acinetobacter baumannii</i>	OXA-58	3	P	N	N	100 (61-100)	100 (61-100)	P	N	N	100 (61-100)	100 (61-100)
	<i>Acinetobacter</i> spp.	OXA-420	3	P	N	N			P	N	N		
NDM-type (n=21)	<i>Acinetobacter</i> spp.	NDM-1	20	N	N	P	100 (84-100)	100 (84-100)	N	N	P	100 (84-100)	100 (84-100)
	<i>Acinetobacter baumannii</i>	NDM-9	1	N	N	P			N	N	P		
Multiples carbapenemase producers (n=29)	<i>Acinetobacter baumannii</i>	OXA-23 + OXA-58	3	P	P	N			P	P	N		
	<i>Acinetobacter baumannii</i>	OXA-23 + OXA-420	3	P	P	N			P	P	N		
	<i>Acinetobacter baumannii</i>	NDM-1 + OXA-23	15	N	P	P			N	P	P		
	<i>Acinetobacter radioresistens</i>	NDM-1 + OXA-23	1	N	P	P			N	N	N		
	<i>Acinetobacter baumannii</i>	NDM-1 + OXA-24	1	P	N	P			P	N	P		
	<i>Acinetobacter</i> spp.	NDM-1 + OXA-58	3	P	N	P			P	N	P		
	<i>Acinetobacter baumannii</i>	NDM-1 + OXA-420	1	P	N	P			P	N	P		
	<i>Acinetobacter baumannii</i>	NDM-5 + OXA-23	1	N	P	P			N	P	P		
	<i>Acinetobacter junii</i>	IMP-37 + OXA-58	1	P	N	N			P	N	N		
Other carbapenemase producers (n=7)	<i>Acinetobacter baumannii</i>	OXA-235	1	N	N	N			N	N	N		
	<i>Acinetobacter pittii</i>	OXA-255	2	P	N	N			P	N	N		
	<i>Acinetobacter pittii</i>	OXA-679	1	P	N	N			P	N	N		
	<i>Acinetobacter baumannii</i>	IMP-63	1	N	N	N			N	N	N		
	<i>Acinetobacter</i> spp.	VIM-4	2	N	N	N			N	N	N		
Non-carbapenemase producers (n=17)	<i>Acinetobacter baumannii</i>	Wild type	1	N	N	N			N	N	N		
	<i>Acinetobacter baumannii</i>	Overexpressed cephalosporinase	5	N	N	N			N	N	N		
	<i>Acinetobacter baumannii</i>	Overproduction of efflux pumps	2	N	N	N			N	N	N		
	<i>Acinetobacter baumannii</i>	CTX-M-15 + CARB-2	1	N	N	N			N	N	N		
	<i>Acinetobacter baumannii</i>	GES-11	1	N	N	N			N	N	N		
	<i>Acinetobacter baumannii</i>	PER-1	1	N	N	N			N	N	N		
	<i>Acinetobacter baumannii</i>	CARB-5	2	N	N	N			N	N	N		
	<i>Acinetobacter baumannii</i>	SHV-12 + CTX-M-15	1	N	N	N			N	N	N		
	<i>Acinetobacter baumannii</i>	TEM-1	2	N	N	N			N	N	N		
	<i>Acinetobacter johnsonii</i>	Wild type	1	N	N	N			N	N	N		